Serum lactate dehydrogenase levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
OBJECTIVE
Clinical laboratory test data obtained prior to treatments were previously analyzed from the standpoint of susceptibility to hypersensitivity reactions in patients treated with the platimun anticancer agent, oxaliplatin (L-OHP). In the present study, the time course from the first to last cycle of the treatment was additionally analyzed to determine a better predictor of these reactions.


METHODS
A total of 20 laboratory test data were obtained from 108 Japanese patients with advanced colorectal cancer who were treated with the L-OHP-containing regimens, FOLFOX4 and/or mFOLFOX6. The averages and variation coefficients (CV%) of the data until the last cycle of the treatment were compared between patients with hypersensitivity reactions and those without.


RESULTS
The average serum lactate dehydrogenase (LDH) level was lower in patients with grade 1/2 reactions (P=0.016), whereas its CV% value was higher in patients with grade 3/4 reactions (P=0.005) than in those without reactions. An increase in serum LDH levels was observed in some patients with grade 3/4 reactions as the cycle number increased, and thereafter hypersensitivity reactions occurred. This phenomenon was not always observed, but was never detected in patients with grade 1/2 reactions.


CONCLUSIONS
Serum LDH levels may be a predictive marker of hypersensitivity reactions in patients treated with L-OHP. Further extensive examinations with a larger number of patients are needed to establish a patient management strategy.
1. Department of Pharmacy, Japan Labour Health and Welfare Organization, Kobe Rosai Hospital, Kobe 651-0053, Japan.
Kyoko
K
Seki
2. Department of Pharmacy, National Hospital Organization Kobe Medical Center, Kobe 654-0155, Japan.
Yasuo
Y
Tsuduki
3. Department of Pharmacy, Kobe University Hospital, Kobe 650-0017, Japan.
Takeshi
T
Ioroi
4. Department of Pharmacy, Japanese Red Cross Kobe Hospital, Kobe 651-0073, Japan.
Michiko
M
Yamane
5. Department of Pharmacy, Shinko Hospital, Kobe 651-0072, Japan.
Hiroko
H
Yamauchi
1. Department of Pharmacy, Japan Labour Health and Welfare Organization, Kobe Rosai Hospital, Kobe 651-0053, Japan.
Yukinari
Y
Shiraishi
1. Department of Pharmacy, Japan Labour Health and Welfare Organization, Kobe Rosai Hospital, Kobe 651-0053, Japan.
Tadaaki
T
Ogawa
2. Department of Pharmacy, National Hospital Organization Kobe Medical Center, Kobe 654-0155, Japan.
Izumi
I
Nakata
3. Department of Pharmacy, Kobe University Hospital, Kobe 650-0017, Japan.
Kohshi
K
Nishiguchi
4. Department of Pharmacy, Japanese Red Cross Kobe Hospital, Kobe 651-0073, Japan.
Teruhisa
T
Matsubayashi
5. Department of Pharmacy, Shinko Hospital, Kobe 651-0072, Japan.
Yoshihide
Y
Takakubo
6. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
Motohiro
M
Yamamori
6. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
Akiko
A
Kuwahara
6. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
Noboru
N
Okamura
3. Department of Pharmacy, Kobe University Hospital, Kobe 650-0017, Japan ; 7. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan ; 8. Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Toshiyuki
T
Sakaeda
D000328:Adult; D000368:Aged; D044466:Asian People; D014408:Biomarkers, Tumor / Q000097:blood; D015179:Colorectal Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D004342:Drug Hypersensitivity / Q000097:blood* / Q000175:diagnosis / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D011379:Prognosis
D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D007770:L-Lactate Dehydrogenase
FOLFOX; colorectal cancer; hypersensitivity reactions; oxaliplatin; serum lactate dehydrogenase level